Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:00 AM
Ignite Modification Date:
2025-12-25 @ 12:00 AM
NCT ID:
NCT02864758
Eligibility Criteria:
Inclusion Criteria:
* Definite non-valvular atrial fibrillation:
* A first reimbursed dispensation of rivaroxaban, dabigatran, or VKA in 2013 or 2014, and
* No previous DOAC (rivaroxaban, dabigatran, apixaban) or VKA dispensation during the previous three years,
* Definite AF information in the database Probable non-valvular atrial fibrillation:-
* A first reimbursed dispensation of rivaroxaban, dabigatran, or VKA in 2013 or 2014, and
* No previous DOAC (rivaroxaban, dabigatran, apixaban) or VKA dispensation during the previous three years,
* Probable AF information in the database (using the development of an AF disease score, see variables definition below),
Exclusion Criteria:
* Patients with Rheumatic valve disease
* Patients with valve replacement
* Patients treated with anticoagulants for venous
* thromboemboslim or prevention of venous
* thromboembolism after orthopedic surgery
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
2 Years
Maximum Age:
99 Years
Study:
NCT02864758
Study Brief:
Protocol Section:
NCT02864758